<DOC>
	<DOCNO>NCT00404820</DOCNO>
	<brief_summary>The aim study examine effect zoledronic acid alendronate bone metabolism measure biomarkers postmenopausal woman osteoporosis .</brief_summary>
	<brief_title>Safety/Efficacy Zoledronic Acid Alendronate Bone Metabolism Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Low bone mineral density ( indicate `` tscore '' 2.0 low ) postmenopausal woman Previous use oral iv bisphosphonates , parathormone , strontium ranelate , sodium fluoride . Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>bisphosphonate</keyword>
	<keyword>biomarker</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>alendronate</keyword>
	<keyword>postmenopausal</keyword>
</DOC>